U.S. Markets closed
  • S&P 500

    4,400.64
    -0.82 (-0.02%)
     
  • Dow 30

    34,930.93
    -127.59 (-0.36%)
     
  • Nasdaq

    14,762.58
    +102.01 (+0.70%)
     
  • Russell 2000

    2,224.96
    +33.12 (+1.51%)
     
  • Crude Oil

    72.37
    +0.72 (+1.00%)
     
  • Gold

    1,806.00
    +6.20 (+0.34%)
     
  • Silver

    25.00
    +0.35 (+1.40%)
     
  • EUR/USD

    1.1853
    +0.0027 (+0.2252%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3902
    +0.0023 (+0.1668%)
     
  • USD/JPY

    109.8980
    +0.1310 (+0.1193%)
     
  • BTC-USD

    39,936.27
    +1,613.16 (+4.21%)
     
  • CMC Crypto 200

    938.33
    +8.40 (+0.90%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Surging Earnings Estimates Signal Good News for Actinium (ATNM)

·2 min read

Actinium Pharmaceuticals, Inc. ATNM is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ATNM’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Actinium could be a solid choice for investors.

Current Quarter Estimates for ATNM

In the past 30 days, one estimate has gone higher for Actinium while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 33 cents a share 30 days ago, to a loss of 30 cents today, a move of 9.1%.

Current Year Estimates for ATNM

Meanwhile, Actinium’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.55 per share 30 days ago to a loss of $1.44 per share today, an increase of 7.1%.

Actinium Pharmaceuticals, Inc. Price and Consensus

Actinium Pharmaceuticals, Inc. Price and Consensus
Actinium Pharmaceuticals, Inc. Price and Consensus

Actinium Pharmaceuticals, Inc. price-consensus-chart | Actinium Pharmaceuticals, Inc. Quote

Bottom Line

The stock has also started to move higher lately, adding 16.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Actinium Pharmaceuticals, Inc. (ATNM) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research